Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
002399.SZ
Shenzhen Stock Exchange9.43
CNY
-0.22
- -
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
002399.SZ
(Shenzhen Stock Exchange)
Recent
price
9.43
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily focused on heparin and its derivatives. Its core offerings include finished dose pharmaceutical products such as enoxaparin sodium injections, prolongin, inhixa, neoparin, and heparin; active pharmaceutical ingredients (APIs) including heparin sodium API, enoxaparin sodium API, and pancreatin API; as well as molecule biologics contract development and manufacturing organization (CDMO) services encompassing research and development, manufacturing, quality management, program management, and technical support. The company also develops innovative drug candidates including apabetalone (RVX-208), a BET bromodomain protein inhibitor in clinical trials for cardiovascular and metabolic diseases, and monoclonal antibodies such as oregovomab. Founded in 1998 and headquartered in Shenzhen, China, Hepalink operates globally with a focus on markets in China, the United States, Europe, and emerging regions, exporting to over 80 countries. The company maintains a robust production capacity, particularly in enoxaparin sodium finished doses, which supports its leadership in the global anticoagulant market. Recent major developments include a strategic focus on international expansion, leveraging Europe as a regional hub and deepening market penetration in China and the U.S., accompanied by a sales growth of over 30% in finished dose pharmaceuticals for the most recent reporting period. Hepalink has enhanced its production capabilities with new formulation production lines to support internationalization initiatives and increase competitiveness. The company announced governance restructuring proposals in 2025, including the abolition of its Supervisory Committee and the election of an independent non-executive director to improve internal governance. Hepalink continues to invest heavily in research and development, dedicating over 10% of annual revenue toward innovation and recently launching new heparin formulations and biosimilar products. Its strategic partnerships include alliances with leading U.S.-based pharmaceutical firms to expand product offerings and enhance global reach. Hepalink’s operational improvements and cost control efforts have contributed to improved gross margins and operational efficiency. Shenzhen Hepalink’s business segments encompass finished dose pharmaceutical products, APIs, CDMO services, and biopharmaceutical research and production, catering to healthcare providers, pharmaceutical companies, and distributors globally. The company’s products primarily address anticoagulation therapies, particularly heparin and low molecular weight heparins (LMWH), with supplementary focus areas in oncology and orthopedics. It supports global healthcare through stringent quality control that meets international regulatory standards, holding certifications from multiple regulatory bodies. The company also promotes sustainability initiatives aimed at reducing carbon emissions and increasing energy efficiency within its manufacturing processes. Overall, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands as a leading global player in the heparin and anticoagulant market, backed by strong R&D capabilities, expansive global distribution, strategic governance updates, and ongoing commitment to innovation and quality manufacturing. It continues to expand its market footprint while enhancing product portfolios and operational excellence to maintain competitive advantage in the pharmaceutical industry.